Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View

Bristol Myers Squibb (BMY) reported strong Q2 2025 results, with adjusted EPS of $1.46 and revenues of $12.3 billion, both exceeding analyst estimates, primarily driven by an 18% surge in its Growth Portfolio sales. Consequently, BMY raised its 2025 revenue guidance to $46.5-$47.5 billion, reflecting better-than-expected performance from both growth and legacy assets. However, the company lowered its 2025 adjusted EPS outlook to $6.35-$6.65 due to a 57-cent per share charge from its recent BioNTech collaboration, indicating a strategic investment impacting near-term profitability while bolstering future pipeline.

Analysis

Bristol Myers Squibb (BMY) delivered a strong second-quarter 2025 performance, exceeding analyst expectations on both revenue and earnings. Total revenues grew 1% year-over-year to $12.3 billion, beating the $11.4 billion consensus, while adjusted EPS of $1.46 surpassed the $1.07 estimate. The key driver of this outperformance was the company's Growth Portfolio, which surged 18% to $6.6 billion, powered by exceptional demand for drugs like Breyanzi (+125%) and Camzyos (+87%). This strength, combined with a slower-than-anticipated decline in the Legacy Portfolio, prompted management to raise its full-year 2025 revenue guidance to a range of $46.5-$47.5 billion. However, the company simultaneously lowered its adjusted EPS outlook to $6.35-$6.65. This reduction is not due to operational weakness but is explicitly attributed to a 57-cent per share acquired IPRD charge from a new strategic co-development partnership with BioNTech. While cost-cutting measures are aiding the bottom line, the company faces headwinds, including gross margin contraction to 72.6% from 75.6% and a recent late-stage clinical trial failure for Reblozyl. These mixed signals occur against a backdrop of significant stock underperformance, with shares down 18.7% year-to-date, contrasting with the industry's 1.5% growth.

Key Decisions for Investors

• Investors should evaluate the lowered 2025 EPS guidance in the context of the strategic IPRD charge from the BioNTech deal, weighing it against the stronger-than-expected operational performance and raised full-year revenue forecast.
• The pronounced 18% growth in the new product portfolio is a critical metric to monitor, as it demonstrates the company's ability to successfully navigate its transition away from legacy assets facing generic competition.
• Given the stock's significant year-to-date underperformance, consider whether the market has overly penalized the non-operational nature of the EPS guidance cut, but remain cautious of execution risks highlighted by the recent Reblozyl study failure and gross margin contraction.